PDS Biotechnology (PDS Biotechnology) Total Current Liabilities : $13.63 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is PDS Biotechnology Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. PDS Biotechnology's total current liabilities for the quarter that ended in Dec. 2023 was $13.63

PDS Biotechnology Total Current Liabilities Historical Data

The historical data trend for PDS Biotechnology's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Total Current Liabilities Chart

PDS Biotechnology Annual Data

Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

Get a 7-Day Free Trial 2.79 3.27 3.76 9.82 13.63

PDS Biotechnology Quarterly Data

Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23

Total Current Liabilities Get a 7-Day Free Trial 9.82 4.13 7.90 9.15 13.63

PDS Biotechnology Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

PDS Biotechnology's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 9.408 + 4.222

+ Other Current Liabilities + Current Deferred Liabilities

= 1.7763568394003E-15 + 0

= 13.63

PDS Biotechnology's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 9.408 + 4.222

+ Other Current Liabilities + Current Deferred Liabilities

= 1.7763568394003E-15 + 0

= 13.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

PDS Biotechnology Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of PDS Biotechnology's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology (PDS Biotechnology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (NAS:PDSB) » Definitions » Total Current Liabilities

Comparable Companies

ATRA PRAX ABOS VAXX LRMR ALT PEPG MRSN ADAP GALT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

EU6:Germany

Address

25B Vreeland Road, Suite 300, Florham Park, NJ, USA, 07932

Website

https://www.pdsbiotech.com

PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

Executives

Spencer D. Brown officer: Senior VP, General Counsel 25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932

Matthew C Hill officer: Chief Financial Officer C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044

Delyle W Bloomquist director, 10 percent owner RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207

Voorhees Seth Van officer: Chief Financial Officer 12 HARVEY DRIVE, SHORT HILLS NJ 07078

Kamil Ali-jackson director C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355

Gregory Gene Freitag director 13631 PROGRESS BLVD., ALACHUA FL 32615

Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327

Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518

Michael N. King officer: Interim Chief Financial Office 303A COLLEGE ROAD EAST, PRINCETON NJ 08540

Ilian Iliev director 303 A COLLEGE ROAD EAST, PRINCETON NJ 08540

Janetta Trochimiuk officer: Principal Accounting Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08540

Richard Sykes director C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932

Frank Bedu-addo director, 10 percent owner, officer: President/CEO 300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922

Lauren Wood officer: Chief Medical Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922

Gregory Conn officer: Chief Scientific Officer 300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922

PDS Biotechnology (PDS Biotechnology) Headlines

From GuruFocus

PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
By Marketwired • 09-06-2023

PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
By Marketwired • 09-06-2023

PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in Clinical Trials
By GuruFocus Research • 11-14-2023

PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
By Marketwired • 08-07-2023

PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023
By Marketwired • 08-02-2023

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Na�ve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA� (pembrolizumab)
By Marketwired • 10-03-2023

PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA� (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023
By Marketwired • 07-25-2023

PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA� (pembrolizumab) in Head and Neck Cancer Patients
By sperokesalga sperokesalga • 04-27-2023

PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
By Marketwired • 08-14-2023

PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)
By Marketwired • 10-02-2023

PDS Biotechnology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Liabilities	Get a 7-Day Free Trial															9.82	4.13	7.90	9.15	13.63

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	9.408	+	4.222
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	1.7763568394003E-15	+	0
	=	13.63

Spencer D. Brown	officer: Senior VP, General Counsel	25B VREELAND ROAD, SUITE 300, FLORHAM PARK NJ 07932
Matthew C Hill	officer: Chief Financial Officer	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Delyle W Bloomquist	director, 10 percent owner	RAYONIER ADVANCED MATERIALS INC., 1301 RIVERPLACE BLVD., SUITE 2300, JACKSONVILLE FL 32207
Voorhees Seth Van	officer: Chief Financial Officer	12 HARVEY DRIVE, SHORT HILLS NJ 07078
Kamil Ali-jackson	director	C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Michael N. King	officer: Interim Chief Financial Office	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Ilian Iliev	director	303 A COLLEGE ROAD EAST, PRINCETON NJ 08540
Janetta Trochimiuk	officer: Principal Accounting Officer	303A COLLEGE ROAD EAST, PRINCETON NJ 08540
Richard Sykes	director	C/O PDS BIOTECHNOLOGY CORPORATION, 25B VREELAND ROAD, FLORHAM PARK NJ 07932
Frank Bedu-addo	director, 10 percent owner, officer: President/CEO	300 CONNELL DRIVE, SUITE 400, BERKELEY HEIGHTS NJ 07922
Lauren Wood	officer: Chief Medical Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922
Gregory Conn	officer: Chief Scientific Officer	300 CONNELL DRIVE, SUITE 4000, BERKELEY HEIGHTS NJ 07922